Front-line clinical treatments for MS including IFN-β, glatiramer acetate, anti–VLA-4 integrin mAb, and fumaric acid esters have been developed, tested, and validated in the MOG-induced EAE model (Aharoni et al., 2008; Galligan et al., 2010; Humphries et al., 2020; Mindur et al., 2014). Here, IFNB1 is linked to myeloid sarcoma.